...

A Phase 1, Open-label, Multicenter Study of ZW171 in Participants With Advanced or Metastatic Ovarian Cancer, Non-small Cell Lung Cancer (NSCLC), and Other Mesothelin Expressing Cancers

Part 1 of the study will evaluate the safety and tolerability of ZW171. Part 2 of the study will evaluate the anti-tumor activity of ZW171 while continuing to evaluate the safety and tolerability.


Why this Research Matters

This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced [inoperable] and/or metastatic) mesothelin-expressing cancers.


Who can Participate

Adult

Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-07203


Study ID

Protocol Number: 24-1477
More information available at ClinicalTrials.gov: NCT06523803

Meet the Team

Image of Principal Investigator

Erin Schenk, MD, PhD

Principal Investigator


Categories

Locations